prikaz prve stranice dokumenta Slower Waning of Anti-SARS-CoV-2 IgG Levels Six Months after the Booster Dose Compared to Primary Vaccination
  Preuzmi
PDF 886.81 KB
Znanstveni rad - Izvorni znanstveni rad
Slower Waning of Anti-SARS-CoV-2 IgG Levels Six Months after the Booster Dose Compared to Primary Vaccination
Vaccines, 10 (2022), 11; 1813. https://doi.org/10.3390/vaccines10111813
Zember, Sanja; Bodulić, Kristian; Balent, Nataša Cetinić; Mikulić, Radojka; Markotić, Alemka; Đaković Rode, Oktavija

Povezani objekti
COVID-19 (zbirka 2.) | Virtualna zbirka

Institucijski repozitorij: Repozitorij Medicinskog fakulteta u Rijeci

Citirajte ovaj rad

Zember, S., Bodulić, K., Balent, N. C., Mikulić, R., Markotić, A. i Đaković Rode, O. (2022). Slower Waning of Anti-SARS-CoV-2 IgG Levels Six Months after the Booster Dose Compared to Primary Vaccination. Vaccines, 10. (11). doi: 10.3390/vaccines10111813

Zember, Sanja, et al. "Slower Waning of Anti-SARS-CoV-2 IgG Levels Six Months after the Booster Dose Compared to Primary Vaccination." Vaccines, vol. 10, br. 11, 2022. https://doi.org/10.3390/vaccines10111813

Zember, Sanja, Kristian Bodulić, Nataša Cetinić Balent, Radojka Mikulić, Alemka Markotić i Oktavija Đaković Rode. "Slower Waning of Anti-SARS-CoV-2 IgG Levels Six Months after the Booster Dose Compared to Primary Vaccination." Vaccines 10, br. 11 (2022). https://doi.org/10.3390/vaccines10111813

Zember, S., et al. (2022) 'Slower Waning of Anti-SARS-CoV-2 IgG Levels Six Months after the Booster Dose Compared to Primary Vaccination', Vaccines, 10(11). doi: 10.3390/vaccines10111813

Zember S, Bodulić K, Balent NC, Mikulić R, Markotić A, Đaković Rode O. Slower Waning of Anti-SARS-CoV-2 IgG Levels Six Months after the Booster Dose Compared to Primary Vaccination. Vaccines [Internet]. 28.10.2022. [pristupljeno 23.12.2024.];10(11). doi: 10.3390/vaccines10111813

S. Zember, K. Bodulić, N. C. Balent, R. Mikulić, A. Markotić i O. Đaković Rode, "Slower Waning of Anti-SARS-CoV-2 IgG Levels Six Months after the Booster Dose Compared to Primary Vaccination", Vaccines, vol. 10, br. 11, Listopad 2022. [Online]. Dostupno na: https://urn.nsk.hr/urn:nbn:hr:184:675710. [Citirano: 23.12.2024.]

Za citiranje koristite ovu mrežnu adresu: https://urn.nsk.hr/urn:nbn:hr:184:675710
Podaci o radu
Naslov (engleski)Slower Waning of Anti-SARS-CoV-2 IgG Levels Six Months after the Booster Dose Compared to Primary Vaccination
AutorSanja Zember
AutorKristian Bodulić
AutorNataša Cetinić Balent
AutorRadojka Mikulić
AutorAlemka Markotić
AutorOktavija Đaković Rode
Autorova ustanovaSveučilište u Rijeci
Medicinski fakultet
(Katedra za zarazne bolesti)
Znanstveno / umjetničko
područje, polje i grana		BIOMEDICINA I ZDRAVSTVO
Kliničke medicinske znanosti
Infektologija
Znanstveno / umjetničko
područje, polje i grana		BIOMEDICINA I ZDRAVSTVO
Temeljne medicinske znanosti
Sažetak (engleski)
Anti-SARS-CoV-2 IgG titer decreases rapidly after primovaccination, leading to a mandatory booster vaccination. We analysed anti-SARS-CoV-2 Spike RBD IgG levels (positive ≥ 50 AU/mL) in 405 healthcare workers (3010 sera) who received a booster dose (BD) 9 months after two-dose BNT162b2 primovaccination. Median antibody titer at the time of BD (582.6 AU/mL) was 1.7-fold and 16.4-fold lower than the peak titer after the first (961.5 AU/mL) and the second vaccine dose (SVD) (10,232.6 AU/mL), respectively. One month after vaccination, IgG titer increased 40.6-fold after BD compared with a 10.8-fold increase after primovaccination. Three months after vaccination, post-booster antibodies decreased significantly slower (2.2-fold) than after primovaccination (3.3-fold). At six months, antibodies decreased slower after BD (4.5-fold; median 5556.0 AU/mL) than after primovaccination (9.6-fold; median 1038.5 AU/mL). Antibody titers before and one month after BD correlated weakly (r = 0.30) compared with a strong correlation (r = 0.65) between the corresponding post-primovaccination titers. Pre-vaccination COVID-19 had no effect on IgG levels after BD compared with a positive effect after primovaccination. Despite high post-booster IgG levels, 22.5% of participants contracted mild COVID-19. The trend of IgG decline indicates the need for further revaccination, but the vaccine type should be defined according to viral mutations.
Ključne riječi (engleski)
Jezikengleski
Vrsta publikacijeZnanstveni rad - Izvorni znanstveni rad
Status objaveObjavljen
Vrsta recenzijeRecenziran - međunarodna recenzija
Verzija publikacijeObjavljena verzija rada (izdavačev PDF)
Naslov časopisaVaccines
Brojčani podacivol. 10, br. 11, 1813
e-ISSN2076-393X
DOIhttps://doi.org/10.3390/vaccines10111813
URN:NBNurn:nbn:hr:184:675710
Datum objave publikacije2022-10-28
ProjektŠifra: KK.011.1.01.0006
Naziv (engleski): Jačanje kapaciteta CerVirVac-a za istraživanja u virusnoj imunologiji i vakcinologiji
Voditelj: Stipan Jonjić
Pravna nadležnost: Hrvatska
Financijer: ERDF
ProjektŠifra: N/A
Naziv (hrvatski): Centar izvrsnosti za virusnu imunologiju i cjepiva
Naziv (engleski): Centre of Excellence for Research in Viral Immunology and the Development of New Vaccines
Kratica: CERVirVac
Voditelj: Stipan Jonjić
Pravna nadležnost: Hrvatska
Financijer: MZOS
Linija financiranja: ZCI
URL dokumentahttps://www.mdpi.com/2076-393X/10/11/1813
Vrsta resursaTekst
Prava pristupaOtvoreni pristup
Uvjeti korištenjaIkona licence Imenovanje 4.0 međunarodna (CC BY 4.0)
Datum i vrijeme pohrane2022-12-09 08:35:04